## Mishaela R Rubin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1349775/publications.pdf

Version: 2024-02-01

49 papers 3,644 citations

201658 27 h-index 214788 47 g-index

50 all docs

50 docs citations

50 times ranked

2699 citing authors

#	Article	IF	CITATIONS
1	The Natural History of Primary Hyperparathyroidism with or without Parathyroid Surgery after 15 Years. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3462-3470.	3.6	505
2	Hypoparathyroidism in the adult: Epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. Journal of Bone and Mineral Research, 2011, 26, 2317-2337.	2.8	485
3	Dynamic and Structural Properties of the Skeleton in Hypoparathyroidism. Journal of Bone and Mineral Research, 2008, 23, 2018-2024.	2.8	176
4	The Role of Parathyroid Hormone in the Pathogenesis of Glucocorticoid-Induced Osteoporosis: A Re-Examination of the Evidence. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4033-4041.	3.6	173
5	The Effect of PTH(1–84) on Quality of Life in Hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2356-2361.	3.6	169
6	Advanced Glycation Endproducts and Bone Material Strength in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2502-2510.	3.6	163
7	Management of Hypoparathyroidism: Present and Future. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2313-2324.	3.6	151
8	Therapy of Hypoparathyroidism with PTH(1–84): A Prospective Four-Year Investigation of Efficacy and Safety. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 137-144.	3.6	148
9	Arterial Stiffness in Mild Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 3326-3330.	3.6	132
10	PTH( $1\hat{a}\in 84$ ) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. Journal of Bone and Mineral Research, 2011, 26, 2727-2736.	2.8	122
11	PTH(1–84) Is Associated With Improved Quality of Life in Hypoparathyroidism Through 5 Years of Therapy. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3694-3699.	3.6	104
12	Therapy of Hypoparathyroidism With PTH( $1\hat{a}\in 84$ ): A Prospective Six Year Investigation of Efficacy and Safety. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2742-2750.	3.6	101
13	The anabolic effects of parathyroid hormone therapy. Clinics in Geriatric Medicine, 2003, 19, 415-432.	2.6	93
14	Three dimensional cancellous bone structure in hypoparathyroidism. Bone, 2010, 46, 190-195.	2.9	84
15	Assessment of bone turnover and bone quality in type 2 diabetic bone disease: current concepts and future directions. Bone Research, 2016, 4, 16001.	11.4	76
16	Parathyroid Hormone as an Anabolic Skeletal Therapy. Drugs, 2005, 65, 2481-2498.	10.9	69
17	Noninvasive Assessment of Skeletal Microstructure and Estimated Bone Strength in Hypoparathyroidism. Journal of Bone and Mineral Research, 2016, 31, 308-316.	2.8	67
18	Advanced Glycation Endproducts and Bone Material Properties in Type 1 Diabetic Mice. PLoS ONE, 2016, 11, e0154700.	2.5	66

#	Article	IF	CITATIONS
19	New anabolic therapies in osteoporosis. Endocrinology and Metabolism Clinics of North America, 2003, 32, 285-307.	3.2	60
20	Bone Cells and Bone Turnover in Diabetes Mellitus. Current Osteoporosis Reports, 2015, 13, 186-191.	3.6	58
21	Human chorionic gonadotropin measurements in parathyroid carcinoma. European Journal of Endocrinology, 2008, 159, 469-474.	3.7	54
22	Therapy of Hypoparathyroidism With rhPTH(1-84): A Prospective, 8-Year Investigation of Efficacy and Safety. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5601-5610.	3.6	53
23	Skeletal changes after restoration of the euparathyroid state in patients with hypoparathyroidism and primary hyperparathyroidism. Endocrine, 2017, 55, 591-598.	2.3	47
24	Skeletal Microstructure and Estimated Bone Strength Improve Following Parathyroidectomy in Primary Hyperparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 196-205.	3.6	45
25	Quality of Life in Hypoparathyroidism Improves With rhPTH(1-84) Throughout 8 Years of Therapy. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2748-2756.	3.6	44
26	Idiopathic osteoporosis in premenopausal women. Osteoporosis International, 2005, 16, 526-533.	3.1	43
27	Rheumatic manifestations of primary hyperparathyroidism and parathyroid hormone therapy. Current Rheumatology Reports, 2002, 4, 179-185.	4.7	29
28	Parathyroid hormone therapy for hypoparathyroidism. Best Practice and Research in Clinical Endocrinology and Metabolism, 2015, 29, 47-55.	4.7	29
29	Trabecular Bone Score in Obese and Nonobese Subjects With Primary Hyperparathyroidism Before and After Parathyroidectomy. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1512-1521.	3.6	27
30	New anabolic therapies in osteoporosis. Current Opinion in Rheumatology, 2002, 14, 433-440.	4.3	25
31	The Effects of Long-term Administration of rhPTH(1-84) in Hypoparathyroidism by Bone Histomorphometry. Journal of Bone and Mineral Research, 2018, 33, 1931-1939.	2.8	24
32	The NO–cGMP–PKG pathway in skeletal remodeling. Annals of the New York Academy of Sciences, 2021, 1487, 21-30.	3.8	23
33	PTH(1-84) replacement therapy for the treatment of hypoparathyroidism. Expert Review of Endocrinology and Metabolism, 2015, 10, 5-13.	2.4	22
34	Robust Trabecular Microstructure in Type 2 Diabetes Revealed by Individual Trabecula Segmentation Analysis of HR-pQCT Images. Journal of Bone and Mineral Research, 2018, 33, 1665-1675.	2.8	22
35	Comparative Effect of rhPTH(1-84) on Bone Mineral Density and Trabecular Bone Score in Hypoparathyroidism and Postmenopausal Osteoporosis. Journal of Bone and Mineral Research, 2018, 33, 2132-2139.	2.8	19
36	Risk factors for lower bone mineral density in older adults with type 1 diabetes: a cross-sectional study. Lancet Diabetes and Endocrinology, the, 2022, 10, 509-518.	11.4	19

#	Article	IF	CITATIONS
37	Effects of Parathyroid Hormone Administration on Bone Strength in Hypoparathyroidism. Journal of Bone and Mineral Research, 2016, 31, 1082-1088.	2.8	18
38	Sarcoidosis within a pituitary adenoma. Pituitary, 2001, 4, 195-202.	2.9	16
39	Use of Cinacalcet and 99mTc-sestamibi Imaging During Pregnancy. Journal of the Endocrine Society, 2017, 1, 1156-1159.	0.2	14
40	Changes in Skeletal Microstructure Through Four Continuous Years of rhPTH(1–84) Therapy in Hypoparathyroidism. Journal of Bone and Mineral Research, 2020, 35, 1274-1281.	2.8	14
41	The potential of parathyroid hormone as a therapy for osteoporosis. International Journal of Fertility and Women's Medicine, 2002, 47, 103-15.	0.4	12
42	Recent advances in understanding and managing hypoparathyroidism. F1000Research, 2020, 9, 766.	1.6	11
43	Biochemical Markers of Bone Turnover in Older Adults With Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2405-e2416.	3 <b>.</b> 6	9
44	In vivo precision of digital topological skeletonization based individual trabecula segmentation (ITS) analysis of trabecular microstructure at the distal radius and tibia by HR-pQCT. Pattern Recognition Letters, 2016, 76, 83-89.	4.2	8
45	Osteoporosis risk in Type 2 diabetes patients. Expert Review of Endocrinology and Metabolism, 2013, 8, 423-425.	2.4	5
46	Effects of the anti-inflammatory drug salsalate on bone turnover in type 2 diabetes mellitus. Endocrine, 2015, 50, 504-507.	2.3	5
47	A Pilot Study of Cognition Among Hypoparathyroid Adults. Journal of the Endocrine Society, 2022, 6, bvac002.	0.2	4
48	Techniques for Studying Bone Anatomy and Function in Humans., 2020,, 404-412.		0
49	Mechanisms of Fracture: Matrix Properties and Cortical Porosity. , 2020, , 449-455.		O